Management Of Postmenopausal Osteoporosis Research Articles

Racial Comparisons Of Postmenopausal Osteoporosis Between African American And Caucasian Women

Background: Osteoporosis is a chronic degenerative metabolic disease of the skeletal system characterized by decreased bone mineral density (BMD), leading to fragile bones prone to fractures. Postmenopausal osteoporosis is particularly prevalent due to the decline in estrogen levels, a hormone essential for maintaining bone health. This study aims to compare the incidence and risk factors of postmenopausal osteoporosis between African American and Caucasian women, focusing on differences in BMD, risk factors, and the effectiveness of screening and treatment methods. Methods and Materials: This research was conducted at the Southeastern Medical Center, Texas, involving 1,000 postmenopausal women aged 60 or older, with equal representation of 500 African American and 500 Caucasian women. Data collection included demographic information, medical history, and BMD measurements using the General Electric LUNAR DPXIQ Model 2288 DEXA device. Statistical analysis was performed using Chi-square and Fisher's assessment tests to evaluate risk factors such as alcohol intake, smoking, medication usage, and comorbidities. BMI and age evaluations were systematized, and the World Health Organization (WHO) guidelines were used to classify osteoporosis and osteopenia. Results: The study revealed that Caucasian women had higher alcohol intake, family history of fractures, and greater use of vitamins, calcium, and hormonal treatments compared to African American women. Conversely, African American women exhibited higher rates of comorbidities like diabetes mellitus, hyperthyroidism, kidney diseases, and rheumatoid arthritis. Despite starting menopause with higher BMD levels, African American women were less likely to be prescribed medication for low BMD. Screening rates and adherence to recommended treatments also varied significantly between the two groups. Conclusion: The findings highlight significant racial disparities in the incidence, risk factors, and management of postmenopausal osteoporosis. Increasing awareness about osteoporosis and promoting lifestyle modifications such as diet, exercise, and cessation of smoking and alcohol consumption can help mitigate these disparities. Future research should focus on developing targeted interventions to improve screening and treatment adherence among African American women, addressing the specific challenges they face in managing bone health.

LncTIMP3 promotes osteogenic differentiation of bone marrow mesenchymal stem cells via miR-214/Smad4 axis to relieve postmenopausal osteoporosis.

Promoting the balance between bone formation and bone resorption is the main therapeutic goal for postmenopausal osteoporosis (PMOP), and bone marrow mesenchymal stem cells (BMSCs) osteogenic differentiation plays an important regulatory role in this process. Recently, several long non-coding RNAs (lncRNAs) have been reported to play an important regulatory role in the occurrence and development of OP and participates in a variety of physiological and pathological processes. However, the role of lncRNA tissue inhibitor of metalloproteinases 3 (lncTIMP3) remains to be investigated. The characteristics of BMSCs isolated from the PMOP rat model were verified by flow cytometry assay, alkaline phosphatase (ALP), alizarin red and Oil Red O staining assays. Micro-CT and HE staining assays were performed to examine histological changes of the vertebral trabeculae of the rats. RT-qPCR and western blotting assays were carried out to measure the RNA and protein expression levels. The subcellular location of lncTIMP3 was analyzed by FISH assay. The targeting relationships were verified by luciferase reporter assay and RNA pull-down assay. The trabecular spacing was increased in the PMOP rats, while ALP activity and the expression levels of Runx2, Col1a1 and Ocn were all markedly decreased. Among the RNA sequencing results of the clinical samples, lncTIMP3 was the most downregulated differentially expressed lncRNA, also its level was significantly reduced in the OVX rats. Knockdown of lncTIMP3 inhibited osteogenesis of BMSCs, whereas overexpression of lncTIMP3 exhibited the reverse results. Subsequently, lncTIMP3 was confirmed to be located in the cytoplasm of BMSCs, implying its potential as a competing endogenous RNA for miRNAs. Finally, the negative targeting correlations of miR-214 between lncTIMP3 and Smad4 were elucidated in vitro. lncTIMP3 may delay the progress of PMOP by promoting the activity of BMSC, the level of osteogenic differentiation marker gene and the formation of calcium nodules by acting on the miR-214/Smad4 axis. This finding may offer valuable insights into the possible management of PMOP.

Management of Postmenopausal Osteoporosis by Moroccan General Practitioners: A Cross-Sectional Survey.

Despite the existence of effective treatments and prescribed therapeutic protocols, there is a lack of management of osteoporosis, resulting in increased secondary morbidity and mortality. The general practitioner (GP) is the first-line practitioner for the detection and management of osteoporosis. This study was conducted to explore the practices, knowledge, and difficulties in postmenopausal osteoporosis management reported by GPs. An anonymous questionnaire (19 questions) was created via Google Forms and distributed to 300 GPs via social networks (WhatsApp, Facebook, and Gmail). The survey results were automatically calculated on "Google Forms" and checked using SPSS.20 software. A total of 129 responses were received, representing a response rate of 43%. The majority of respondents were women (67.2%). The definition of osteoporosis was variable, with 51.6% defining it as a T-score of ≤-2.5 SD, 25.8% defining it as diffuse bone demineralization, and 12.1% defining it as a fracture after falling with low energy. Prolonged corticosteroid therapy was the most commonly indicated reason for measuring bone mineral density (BMD) (81.39%). The calcium phosphate balance was the most requested (90.1%). Vitamin D and calcium supplementation were reported by 74.41% and 54.26% of GPs, respectively. Fracture of the upper end of the femur was the main therapeutic indication (65.11%). Most GPs surveyed (73.3%) were unfamiliar with the fracture risk assessment tool (FRAX). Most of the GPs gave advice on fall prevention to their patients (83.72%), and 62.5% of GPs monitored their patients' height. Anti-osteoporosis treatment was maintained for 3 to 5 years by 44.96% of GPs. Our survey found that the practices and knowledge of GPs on osteoporosis vary widely and often deviate from the recommended standards. This highlights the need for more excellent education of GPs, due to their vital role in the management of osteoporosis.

Postmenopausal Osteoporosis: Menopause Hormone Therapy and Selective Estrogen Receptor Modulators.

Osteoporosis is a debilitating silent disease with a huge socio-economic impact. Prevention strategies and early detection of osteoporosis need to be carried out in every health care unit to substantially reduce the fracture rates. Indian studies have indicated a knowledge gap on diagnosis and management of osteoporosis amongst medical professionals and consumers. This article reviews the evidences available on searches from PubMed and The National Library of Medicine, author's opinions based on clinical experience. There is a need for escalating the efforts to bridge the knowledge gap regarding various aspects of osteoporosis amongst professionals and consumers. Three indications for postmenopausal hormone therapy (HT), which have constantly withstood the test of time, are symptom relief, urogenital atrophy, and bone health. This article specifically focuses on management of postmenopausal osteoporosis by HT alone or in combinations. Early menopause is within 10years of menopause and late menopause is considered beyond 10years of menopause. HT is a cost-effective therapy in the early post menopause especially in symptomatic women at risk for osteoporosis unless contraindicated. HT prevents all osteoporotic fractures even in low-risk population. All HT preparations including low dose and non-oral routes of estrogen are effective for bone health. The bone protective effect lasts while on HT. Extended use of HT in women after 10years of menopause with reduced bone mass is an option after detailed counselling of the risk benefit analysis compared with the other available therapies for osteoporosis. The primary therapy to prevent bone loss in women with premature menopause and secondary amenorrhea is HT. HT work up and annual follow-up is essential before prescribing HT.

Guideline for diagnostic, prevention and treatment of postmenopausal osteoporosis

Background. Postmenopausal osteoporosis (PMO), which is developed due the estrogen defi ciency in women after menopause, is the most common type of systemic osteoporosis. The latest Ukrainian recommendation for its management requires revision due to new data from high-quality research performed in recent years. The purpose was to develop a guideline on the diagnosis, prevention, and treatment of PMO based on an analytical analysis of modern literary sources in order to improve the awareness of the medical community of Ukraine. Methodology. To develop the guideline, an expert group of 13 leading Ukrainian scientists of various specialties was created who conducted a tho rough review of modern literature on this topic, assessed the level of existing evidence using the GRADE system, proposed and voted on 15 recommendations of the guideline. Results. The guideline contains chapters on diagnosis and diff erential diagnosis of PMO, assessment of the osteoporotic fracture risk, the role of bone turnover markers in the management of PMO, and modern strategies of antiosteoporotic treatment. Conclusions. The Ukrainian guideline on the diagnosis, prevention, and treatment of PMO, which contains 15 main recommendations, created on the basis of a tho rough analysis and synthesis of modern literature data, is an important tool for the management of PMO and is recommended by Ukrainian Association of Osteoporosis for use in Ukrainian me dical community.

Expression of Concern: Comparative evaluation of isosorbide mononitrate and alendronate in management of postmenopausal osteoporosis.

Expression of Concern: Comparative evaluation of isosorbide mononitrate and alendronate in management of postmenopausal osteoporosis.

Bone Turnover Markers for Diagnosis of postmenopausal osteoporosis – A review

Postmenopausal osteoporosis is an age related skeletal metabolic disorder that affects most elderly women worldwide owing to the loss of estrogen activity, increase in bone turnover rate and circulating level of bone turnover markers. Although osteocalcin, bone specific alkaline phosphatase, and pro-collagen type I N- and C-terminal pro-peptides are considered as the most sensitive markers of bone formation however, they suffer some limitations. Consequently, periostin, sclerostin and dickkopf-1 protein (Dkk-1) are emerging diagnosis markers of bone pathologies and monitoring therapeutic interventions and management of postmenopausal osteoporosis. These markers serve as effective tools for diagnosis of bone disorders, predict reduction in fracture risk, reflect metabolic effect of drugs during bone remodeling and could be used to establish the lowest dose that elicit the required change in bone mineral density. Biological variability from different sources including controllable and uncontrollable factors could serve as the major limitations of these established markers of bone formation (BFMs). This review, therefore focus on the therapeutic applications of selected bone turnover markers for early diagnosis of postmenopausal osteoporosis.

Age-specific bone turnover prevalence in women with post-menopausal osteoporosis: possibilities of traditional plant therapy during COVID-19 pandemic

Post-menopausal osteoporosis is a chronic age-related illness marked by a decrease of bone density and quality, as well as a higher risk of fragility fractures. Fragility fractures are recognized to have a major impact on individuals and society both personal and financially. In recent years, it has been a hidden epidemic impacting over 200 million people globally. It is claimed that one osteoporosis fracture happens every three seconds throughout the world. The termination of ovarian hormone production, which causes rapid bone loss, puts postmenopausal women at greater risk of developing osteoporosis. The gradual changes in structure, quality and density of the bones lead to the fracture and a rise in morbidity and death among menopausal women. Interventions that enhance a woman’s well-being and quality of life by reducing the intensity and frequency of post-menopausal osteoporosis. Hormone therapy is helpful in managing menopausal symptoms; nevertheless, it has been linked to a number of potentially significant side effects, including the development of ovarian and breast cancer. As a result, there has been an increase in demand for alternative treatment options. Plant species with potential antiosteoporosis characteristics are highlighted and further discussed in order to aid future medication development for treating this illness. Many plants and there components have been demonstrated to have antiosteoporosis action based on a vast number of chemical and pharmacological studies. Plant-derived molecules have lately piqued the curiosity of researchers working on novel medicinal agents. As a result, therapeutic interventions that can delay reduce or prevent bone loss in ageing people, especially postmenopausal women, are essential to a person’s well-being and quality of life. The plants included in this review are those that have been frequently used in traditional medicine and have shown clinical efficacy in the management of post-menopausal osteoporosis. While numerous plants can prevent and treat osteoporosis, only a fraction of plants have been discussed, including their origin, active components, and pharmacological activity, we evaluated the challenges and methods utilized in the therapy of postmenopausal osteoporosis during the COVID-19 pandemic.

Efficacy and safety of Chinese herbal medicine Buzhong Yiqi decoction for postmenopausal women with osteoporosis: A protocol for systematic review and meta-analysis.

Postmenopausal osteoporosis (PMOP) is a disorder of bone metabolism caused by estrogen deficiency in women after menopause, which manifests clinically as pain, spinal deformities, and even fragility fractures, affecting the quality of life of patients and possibly shortening their life span. Traditional Chinese medicine prescription Buzhong Yiqi Decoction (BZYQD) has been widely used in clinical practice and achieved good results. But there is no high-level evidence to support this result. The aim of this study is to evaluate BZYQD's efficacy and safety in the management of PMOP. We will search articles in 7 electronic databases including Chinese National Knowledge Infrastructure, Wanfang Data, Chinese Scientific Journals Database, Chinese databases SinoMed, PubMed, Embase, and Cochrane Library databases. All the publications, with no time restrictions, will be searched without any restriction on language and status, the time from the establishment of the database to September 2022. Two reviewers will independently assess the quality of the selected studies, NoteExpress and Excel software will be used to extract data, and the content will be stored in an electronic chart. Different researchers will separately screen the titles and abstracts of records acquired potential eligibility which comes from the electronic databases. Full-text screening and data extraction will be conducted afterward independently. Statistical analysis will be conducted using RevMan 5.4 software. This study will evaluate the efficacy and safety of BZYQD in the treatment of PMOP, to provide high-quality, evidence-based clinical recommendations. The study provides a trustable clinical foundation for BZYQD in the treatment of PMOP.

ACOG Clinical Practice Guideline No. 2: Management of Postmenopausal Osteoporosis: Correction.

ACOG Clinical Practice Guideline No. 2: Management of Postmenopausal Osteoporosis: Correction.

Menopause Hormone Therapy in the Management of Postmenopausal Osteoporosis.

This narrative review analyzes the customization of menopause hormone therapy (MHT) for osteoporosis prevention and treatment in the context of the patients' age and menopausal age. In short, MHT is indicated in most women suffering from menopause before the age of 45 years except for breast cancer survivors. These women should be treated with MHT until the age of 50 years. For women who have entered menopause at around the age of 50 years, risks associated with MHT are low, and MHT is a safe option, provided there is an indication for it. We suggest that pursuing MHT entails different risks than initiating it, after the age of 60 years. In both cases, advantages and risks should be evaluated. We suggest using risk calculators to assess the magnitude of these risks and choosing regimens that entail the lowest breast and thrombosis risks.

Management of Postmenopausal Osteoporosis: ACOG Clinical Practice Guideline No. 2.

To provide updated evidence-based recommendations for the treatment of postmenopausal osteoporosis. Postmenopausal patients with primary osteoporosis. This guideline was developed using an a priori protocol in conjunction with a writing team consisting of two specialists in obstetrics and gynecology appointed by the ACOG Committee on Clinical Practice Guidelines-Gynecology and one external subject matter expert. ACOG medical librarians completed a comprehensive literature search for primary literature within Cochrane Library, Cochrane Collaboration Registry of Controlled Trials, EMBASE, PubMed, and MEDLINE. Studies that moved forward to the full-text screening stage were assessed by two authors from the writing team based on standardized inclusion and exclusion criteria. Included studies underwent quality assessment, and a modified GRADE (Grading of Recommendations Assessment, Development, and Evaluation) evidence-to-decision framework was applied to interpret and translate the evidence into recommendation statements. This Clinical Practice Guideline includes updated recommendations on who should receive osteoporosis pharmacotherapy, the benefits and risks of available pharmacotherapy options, treatment monitoring and follow-up, and the role of calcium and vitamin D in the management of postmenopausal osteoporosis. Recommendations are classified by strength and evidence quality. Ungraded Good Practice Points are included to provide guidance when a formal recommendation could not be made because of inadequate or nonexistent evidence.

Comparative study to evaluate the efficacy of panchtikta ghrita and bisphosphonate in the management of postmenopausal osteoporosis (asthikshaya)

Asthikshaya is a disorder related to bone degeneration. It is similar to osteoporosis. A disturbance in bone remodeling is the underlying mechanism for decrease in normal bone density. Osteoporosis is caused due to low bone mass, and micro architectural breakdown of bone tissue. In India, Osteoporosis is an emerging public health problem with increasing numbers of elderly. Women are more prone as compared to men. Risk of Osteoporosis even increases at the stage of menopause, which is physiological transition period of hormonal imbalance. Aims and objectives: To compare the efficacy of Panchtikta Ghrita and Bisphosphonate in the management of Postmenopausal osteoporosis (Asthikshaya). Methodology: For proposed study,Postmenopausal womenwill be assessed for BMD by organizing special camp for assessment of BMD, Recruitment of women having T‟ score -2.5 to -1 subjects will be randomly divided into two groups. Group A will be given Panchtikta Ghritain the dose of 15 ml orally on empty stomach for 90 days and Group B will be given Bisphosphonate (as a standard drug)in dose of 70 mg orally once weekly on an empty stomachfor 90days.The record of assessment willbe taken at zero day, 30th day, 60th day and 90th day.

Fabrication and optimization of raloxifene loaded spanlastics vesicle for transdermal delivery

This research work is envisioned for the development and optimization of Raloxifene HCL loaded spanlastics. Raloxifene HCL, a selective estrogen receptor modulator (SERM), is active for the deterrence and management of postmenopausal osteoporosis. Spanlastics nanocarrier was prepared by ethanol injection method and optimized for independent variables by using Box Behnken design. The independent variables used in the experiment were concentration of Span 60, Tween 80 as an edge activator, and sonication time. The individual and joined impacts of independent variables were assessed on vesicle size, polydispersity index (PDI), and encapsulation efficiency (EE). Raloxifene HCL and formulation were analyzed by FT-IR, DSC and XRD. Raloxifene HCL loaded spanlastics were characterized for particle size, PDI, EE, and in-vitro drug release. Ex vivo skin permeation and stability studies were performed for the optimized formulation. The optimized spanlastics vesicle showed a particle size of 275.4 nm with PDI, 0.267 which was suitable for permeation through skin layers. TEM image illustrated well-dispersed nanocarrier with spherical shape. The % cumulative drug release and transdermal flux for the optimized spanlastics formulation were found to be 85% (Approx. after 24 h) and 4.24 μg/cm2/hr respectively. The enhanced permeation across the skin layers was proposed to be due to the presence of ethanol which will increase the lipid fluidity of the stratum corneum and will help to penetrate the drug. Later the skin penetration ability was determined by confocal laser scanning microscopy (CLSM) and showed that rhodamine loaded spanlastics formulation penetrated to the depth of 54.9 μm while rhodamine suspension limited to 20 μm in the skin. We can conclude that raloxifene HCL loaded spanlastics could serve as a better approach to deliver drug in deeper layers of the skin.

Breastfeeding and Postmenopausal Osteoporosis

Although pregnancy and breast-feeding involve adequate calcium mobilization, it is not recognized if these affect the acquisition of a healthy peak bone mass (PBM) and, hence, postmenopausal osteoporosis (PMOP). The aim of this review was to evaluate osteoporosis in postmenopausal women and its association with breastfeeding. Searches were conducted in PubMed Central and Scopus to find relevant literature and studies. Searching terms were “osteoporosis” AND “breastfeeding. There was no time restriction applied. Language was restricted to English, German and Greek. Results from different studies evaluating the association of breastfeeding and osteoporosis in women are contradictory. While some show a beneficial and protective effect of breastfeeding, others show a detrimental impact and some studies show no association at all. Postmenopausal osteoporosis (PMOP) has long been a pervasive public health concern and the prevention, assessment and management of postmenopausal osteoporosis is particularly important. Thus, more research is needed on the association of breastfeeding and osteoporosis to be able to give accurate recommendations to women.

Revisiting Ipriflavone: a Potential Isoflavone for the Management of Postmenopausal Osteoporosis

Revisiting Ipriflavone: a Potential Isoflavone for the Management of Postmenopausal Osteoporosis

A quinoxaline-based compound ameliorates bone loss in ovariectomized mice.

DMB (6,7-dichloro-2-methylsulfonyl-3-Ntert-butylaminoquinoxaline) is a quinoxaline-based compound that has been investigated as a glucagon-like peptide-1 receptor (GLP-1R) agonist. To clarify anti-osteoporosis effect of DMB, an osteoporotic mice model was established by ovariectomy (OVX) operation. The OVX mice were given intraperitoneally DMB, exendin-4 (EX-4), or 17β-estradiol (E2) for two months. Then bone mass and structure, and bone morphometric parameters were examined by micro-CT. Weight gain and food consumption, bone turnover markers, and biomechanical strength of the femur were tested, and bone histomorphometry was analyzed. The food intake and weight gain was obviously reduced by E2 or EX-4, but not DMB. However, DMB or EX-4 treatment obviously inhibited skeletal deterioration and enhanced bone strength. The improvement involved in the increased osteoblast number and level of bone formation markers, and reduced osteoclasts number and level of bone resorption markers. In addition, DMB was found to stimulate osteoblastogenesis-related marker gene expression. These results demonstrated that DMB ameliorated bone loss mainly via induction of bone formation, which suggests that the small molecule compound might be applied to the management of postmenopausal osteoporosis.

Egyptian consensus on treat-to-target approach for osteoporosis: a clinical practice guideline from the Egyptian Academy of bone health and metabolic bone diseases

BackgroundThis study was carried out to achieve an Egyptian expert consensus on a treat-to-target management strategy for osteoporosis using Delphi technique. A scientific committee identified researchers and clinicians with expertise in osteoporosis in Egypt. Delphi process was implemented (2 rounds) to establish a consensus on 15 clinical standards: (1) concept, (2) diagnosis, (3) case identification, (4) whom to treat, (5) who should treat?, (6) case stratification and intervention thresholds, (7) falls risk, (8) investigations, (9) treatment target, (10) management, (11) optimum treatment duration, (12) monitoring, (13) drug holiday, (14) osteoporosis in men, and (15) post-fracture care and fracture liaison service.ResultsThe surveys were sent to an expert panel (n = 25), of whom 24 participated in the two rounds. Respondents were drawn from different governorates and health centres across Egypt including the Ministry of Health. Most of the participants were rheumatologists (76%), followed by internists (8%), orthopaedic doctors (4%), rehabilitation doctors (4%), primary care (4%), and ortho-geriatrics (4%) physicians. Seventy-two recommendations, categorised into 15 sections, were obtained. Agreement with the recommendations (rank 7–9) ranged from 83.4 to 100%. Consensus was reached (i.e. ≥ 75% of respondents strongly agreed or agreed) on the wording of all 15 clinical standards identified by the scientific committee. An algorithm for the management of postmenopausal osteoporosis has been suggested.ConclusionA wide and representative panel of experts established a consensus regarding the management of osteoporosis in Egypt. The developed guidelines provide a comprehensive approach to the assessment and management of osteoporosis for all Egyptian healthcare professionals who are involved in its management.

Patterns of Teriparatide and Sequential Antiresorptive Agent Treatment Among Elderly Female Medicare Beneficiaries.

The 2020 American Association of Clinical Endocrinologists guidelines for assessing osteoporosis among postmenopausal women stratified postmenopausal women with osteoporosis to "high" and "very-high" fracture risk categories and recommended anabolic agents as initial therapy followed by an antiresorptive agent. Switching the order can blunt the effect of anabolic agents, and failing to follow with an antiresorptive can lead to loss of bone generated by the anabolic agent. It would be helpful to understand the real-world prescribing patterns of anabolic agents. Using the 2010-2015 Medicare 100% osteoporosis database, we assessed patient profiles, teriparatide prescribers, persistence of teriparatide therapy, and antiresorptive agent use after teriparatide discontinuation among elderly women who initiated teriparatide from 2011 to 2013. This study included 14,786 patients. In the year before teriparatide initiation, 30.0% of them had a fracture, 67.6% had a dual energy x-ray absorptiometry scan, 74.4% had a diagnosis of osteoporosis, and 47.9% used antiresorptive agents (non-naïve teriparatide users). Among those who had fractures, 49.4% initiated teriparatide within 3 months postfracture. Teriparatide was prescribed for 37% of users by primary care doctors, 19% by rheumatologists, 13% by endocrinologists, and 7.0% by orthopedists. Median time of teriparatide use was 7.2 months. After teriparatide discontinuation, 40.8% switched to antiresorptive agents (31.9% among naïve teriparatide users, 50.5% among non-naïve users). Among switchers, 42.5% switched within 60 days, 50.5% switched to denosumab, and 31.6% switched to oral bisphosphonates. This study of real-world prescribing data found that about half of teriparatide users switched from an antiresorptive agent, and less than half switched to antiresorptive agents after teriparatide discontinuation. Persistence of teriparatide use was suboptimal. In the management of postmenopausal osteoporosis, increasing the persistence of teriparatide use and improving the appropriate treatment sequence of anabolic and antiresorptive drugs are critical to maximizing gains in bone mass, providing the greatest protection against fractures. © 2021 American Society for Bone and Mineral Research (ASBMR).

MILK-DERIVED BIOACTIVE PEPTIDES WITH ANTIOSTEOPOROTIC EFFECT: A MINI REVIEW

Postmenopausal osteoporosis is a global health problem characterized by decreased in bone mineral density (BMD) and progressive deterioration of microarchitecture and subsequent increase in bone fragility and susceptibility to fracture. More than 200 million people suffer from osteoporosis worldwide with about 8.9 million fractures and the prevalence rate of osteoporosis is expected to increase significantly in the future because of increased in life expectancy and aging population. Milk-derived bioactive peptides from cow, goat, sheep, buffalo, and camel exhibit several potential health promoting effect including antiosteoporosis, antihypertensive, antioxidative, antithrombotic, immunomodulatory and anti-inflammatory effects. Epidemiological and intervention studies have shown that milk and milk-derived peptides prevented bone loss in pre- and postmenopausal women. Moreover, quite a lot of studies have reported that milk-derived bioactive peptides can induce osteoblast cell proliferation, differentiation and also prevented bone loss in osteoporotic rats model. Thus, milk-derived peptides exhibits beneficial effect against bone-related diseases and can be of particular interest towards prevention and management of postmenopausal osteoporosis. Hence, the present review summarizes various studies using ISI, SCOPUS and PubMed indexed journals to elucidate the potential role of milk-derived bioactive peptides with in vitro and in vivo antiosteoporotic property